BOTOX® COSMETIC onabotulinumtoxinA injection | JUVÉDERM® COLLECTION OF FILLERS

A DUO TO TALK ABOUT

Stephanie was treated with BOTOX® Cosmetic in the forehead lines, lateral canthal lines, and glabellar lines, along with JUVÉDERM® VOLUMA® XC in the cheeks, JUVÉDERM® VOLLURE® XC in the nasolabial folds, and JUVÉDERM® VOLBELLA® XC in the lips.
Real patient. ***Results may vary.***

The safety and efficacy of these products for combined use have not been studied.

This information is not a clinical recommendation. Each clinician is responsible for making appropriate decisions for patients under their care.

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

BOTOX® Cosmetic (onabotulinumtoxinA) Important Information

Indications
BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:
- Moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- Moderate to severe lateral canthal lines associated with orbicularis oculi activity
- Moderate to severe forehead lines associated with frontalis activity

Please see additional Important Safety Information throughout for BOTOX® Cosmetic and the JUVÉDERM® Collection of Fillers.

A DUO That Starts With Your Expertise

Patients want full-face assessments and your recommendation

94% are interested in a full-face assessment[1,*]

82% take action (receive treatment or book an appointment) after a specialist conducts a full-face assessment[2,†]

85% who decide to get filler do so either immediately or within 1 to 6 months of their initial neurotoxin treatment[2,‡]

Provider trust is the main factor that helps neurotoxin patients move forward with filler treatment[2,§]

Deliver personalized results with proven safety

Neurotoxin patients cite safety and results as more important than duration or cost[3,‖]

Filler patients prioritize safety and smooth, long-lasting, natural-looking results[1,¶]



Allergan Medical Institute offers education on **85%** of the face to treat patients' aesthetic concerns[4]

*According to a 2021 online survey of 300 patients. Includes filler patients who said they were extremely, very, or somewhat interested.
†According to a 2020 online survey of 241 specialists asked what percentage of the time do their new/naïve patients with whom they've discussed a full facial consultation convert to treatment right away or make a future appointment.
‡According to a 2021 online survey of 239 NTX patients who decided to get filler treatment.
§According to a 2020 online survey of 241 specialists asked what are the main factors that help patients move forward with adding on a filler treatment. Physician trust was the highest rated driver at 68%.
‖According to a 2021 online survey of 526 neurotoxin users.
¶According to a 2021 online survey of 300 filler users.

BOTOX® Cosmetic (onabotulinumtoxinA) IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS
BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

WARNINGS AND PRECAUTIONS
Lack of Interchangeability Between Botulinum Toxin Products
The potency units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported. Patients or caregivers should be advised to seek immediate medical care if swallowing, speech, or respiratory disorders occur.

Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX® The safety and effectiveness of BOTOX® for unapproved uses have not been established.

Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Cardiovascular System
There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Use caution when administering to patients with pre-existing cardiovascular disease.

Increased Risk of Clinically Significant Effects With Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see *Warnings and Precautions*).

Please see additional Important Safety Information for BOTOX® Cosmetic (onabotulinumtoxinA) and the JUVÉDERM® Collection of Fillers on following pages.

A DUO of Opportunities

When patients start with BOTOX® Cosmetic (onabotulinumtoxinA)

BOTOX® Cosmetic and JUVÉDERM® are the **most requested brands**[3,5,*]

BOTOX® Cosmetic patients receive JUVÉDERM® for their filler treatment **more than half the time**[2,†]



*Based on a 2020 online survey of 526 neurotoxin users. Patients were asked if they ever requested to receive a specific brand of neurotoxin, and if so, which brand. And in a national online survey of 242 healthcare professionals, HCPs reported Juvéderm® products are requested more than any other filler brands.
†According to a 2020 online survey of 222 specialists asked of their patients who receive both neurotoxin and fillers, if they receive BOTOX® Cosmetic first, which brand of filler do they subsequently receive.

‡According to a 2020 online chart survey of 366 healthcare providers who reported the yearly practice spend of BOTOX® Cosmetic-only patients (n = 1,760) vs dual-use BOTOX® Cosmetic and JUVÉDERM® patients (n = 343).

When patients start with JUVÉDERM®

The more syringes of JUVÉDERM® a patient purchases, the **more likely** they are to also purchase BOTOX® Cosmetic[7,§]

of patients who purchased **1 syringe** of JUVÉDERM® also purchased BOTOX® Cosmetic

of patients who purchased **4+ syringes** of JUVÉDERM® also purchased BOTOX® Cosmetic

§According to a 2019 survey on JUVÉDERM® consumer usage.

A DUO to Build Long-term Relationships

Dual-use patients are more loyal to the practice[8]

In a large, multicenter, international retrospective review, a higher percentage of dual-use patients stay with the same practice at 1 and 5 years.[8,*]

Patient retention rate at 1 and 5 years[8]



Neuromodulator (NM) alone ($P < 0.0001$).
Hyaluronic acid (HA) soft-tissue filler alone ($P < 0.0001$).

BOTOX® Cosmetic patients add **6.76 other Allergan Aesthetics treatments** with their same providers over 2.5 years[9]

*Based on a multicenter, retrospective review of patient retention rates from 7 aesthetic practices across 5 continents, incorporating more than 2600 patients. Patients who received one or more treatments with hyaluronic acid soft-tissue (HA) fillers or neuromodulators (NM) were retrospectively divided into 1 of 3 groups according to treatment(s) received over a 12-month period: NM only, HA only, or combination treatment with NM and HA. Retention rates in each practice at 1, 3, and 5 years after the incident year were calculated as the proportion of patients in each group who received at least one paid treatment in the 12-month period leading up to each time point.

BOTOX® Cosmetic (onabotulinumtoxinA) IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS

Dysphagia and Breathing Difficulties
Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see *Boxed Warning*).

Pre-existing Conditions at the Injection Site
Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

Dry Eye in Patients Treated With BOTOX® Cosmetic
There have been reports of dry eye associated with BOTOX® Cosmetic injection in or near the orbicularis oculi muscle. If symptoms of dry eye (eg, eye irritation, photophobia, or visual changes) persist, consider referring patients to an ophthalmologist.

Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Please see additional Important Safety Information for BOTOX® Cosmetic (onabotulinumtoxinA) and the JUVÉDERM® Collection of Fillers on following pages.

A DUO for You to Choose

BOTOX® COSMETIC onabotulinumtoxinA injection | THE LOOK OF 3

Choose BOTOX® Cosmetic to temporarily improve the appearance of the

UPPER FACE

moderate to severe

- **Forehead lines**
- **Lateral canthal lines**
- **Glabellar lines**

The Look of 3 is a BOTOX® Cosmetic treatment of 3 areas, 64 Units, at least 3 times a year.[10]

Only BOTOX® Cosmetic offers precise dosing for similar results across cycles with simultaneous treatment in 3 areas.[10-13]

Stephanie was treated with BOTOX® Cosmetic in the forehead lines, lateral canthal lines, and glabellar lines, along with JUVÉDERM® VOLUMA® XC in the cheeks, JUVÉDERM® VOLLURE® XC in the nasolabial folds, and JUVÉDERM® VOLBELLA® XC in the lips. **Results may vary.**

The safety and efficacy of these products for combined use have not been studied.

BOTOX® Cosmetic (onabotulinumtoxinA) IMPORTANT SAFETY INFORMATION (continued)

ADVERSE REACTIONS

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for glabellar lines were eyelid ptosis (3%), facial pain (1%), facial paresis (1%), and muscular weakness (1%).

The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%), and eyelid ptosis (2%).

DRUG INTERACTIONS

Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.

JUVÉDERM®

COLLECTION OF FILLERS

Choose JUVÉDERM® for the

MID & LOWER FACE

JUVÉDERM® offers 5 long-lasting fillers that add volume to lift, smooth, plump, or contour to meet your patients' unique needs.[14-18]

JUVÉDERM® VOLUMA® XC	***Structural*** gel for adding volume, lift, and contour to the cheeks and chin[14]
JUVÉDERM® ULTRA PLUS XC	***Robust*** gel for wrinkles and folds[15]
JUVÉDERM® VOLLURE® XC	***Smooth*** and ***balanced*** gel for wrinkles and folds[16]
JUVÉDERM® ULTRA XC	***Plump*** gel for lip augmentation[17]
JUVÉDERM® VOLBELLA® XC	***Soft*** and ***subtle*** gel for lips, perioral lines, and infraorbital hollows[18]

This information is not a clinical recommendation. Each clinician is responsible for making appropriate decisions for patients under their care.

USE IN SPECIFIC POPULATIONS

There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.

Please see accompanying BOTOX® Cosmetic full Prescribing Information, including Boxed Warning, or visit https://www.rxabbvie.com/pdf/botox-cosmetic_pi.pdf

Please see Important Safety Information for the JUVÉDERM® Collection of Fillers on following pages.

RECOMMEND THE #1 CHOSEN DERMAL FILLER COLLECTION[19,*]

to deliver optimal outcomes based on patients' treatment goals

Enhance and augment

or

Treat and correct

Every discussion with your patients is an opportunity

*Based on market share of filler brands in 2021.

BOTOX® COSMETIC onabotulinumtoxinA injection

moderate to severe

FOREHEAD LINES (20 Units)

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum eyebrow elevation before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30, 61% (178/290) and 46% (145/318) of patients demonstrated a ≥ 2-grade improvement from baseline in forehead line severity at maximum eyebrow elevation as compared to 0% (0/101) and 1% (1/156) in placebo, as assessed by both investigators and subjects.[10]

moderate to severe

LATERAL CANTHAL LINES (24 Units)



Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum smile before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30, 26.1% (58/222) and 20.3% (62/306) of patients demonstrated a ≥ 2-grade improvement from baseline in lateral canthal line severity at maximum smile as compared to 1.3% (3/223) and 0% (0/306) in placebo, as assessed by both investigators and subjects.[10]

moderate to severe

GLABELLAR LINES (20 Units)



Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum frown before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30 as assessed by investigators, 80% (325/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 3% (4/132) in placebo. In clinical trials at Day 30 as evaluated by patients, 89% (362/405) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 7% (9/132) in placebo.[10]

JUVÉDERM®

COLLECTION OF FILLERS

Real patient. ***Results may vary.***
Treated with JUVÉDERM® 3 months after treatment with BOTOX® Cosmetic.

Unretouched photos of paid model taken before and 1 month after treatment. A total of 3.0 mL of JUVÉDERM® VOLUMA® XC was injected into the cheek area. A total of 0.6 mL of JUVÉDERM® Ultra XC was injected into the oral commissures and lips (vermilion body and Cupid's bow) for lip augmentation.

In the JUVÉDERM® VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.[14]

Real patient. ***Results may vary.***
Unretouched photos taken before and 1 month after treatment. A total of 0.6 mL of JUVÉDERM® Ultra XC was injected into the oral commissures and lips (vermilion body and Cupid's bow) for lip augmentation.

Murielle, 27

Murielle was treated with BOTOX® Cosmetic in the forehead lines, lateral canthal lines, and glabellar lines, along with JUVÉDERM® VOLUMA® XC in the cheeks and JUVÉDERM® Ultra XC in the lips.
Results may vary.

The safety and efficacy of these products for combined use have not been studied.

JUVÉDERM® Collection of Fillers Important Information

INDICATIONS

JUVÉDERM® VOLUMA® XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face and for augmentation of the chin region to improve the chin profile in adults over the age of 21.

JUVÉDERM® VOLLURE® XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.

JUVÉDERM® VOLBELLA® XC injectable gel is indicated for injection into the lips for lip augmentation and correction of perioral rhytids, and for the improvement of infraorbital hollowing in adults over the age of 21.

JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

JUVÉDERM® Ultra XC injectable gel is also indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

Please see additional Important Safety Information for the JUVÉDERM® Collection of Fillers on following pages.

BOTOX® COSMETIC onabotulinumtoxinA injection

moderate to severe

FOREHEAD LINES (20 Units)

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum eyebrow elevation before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30, 61% (178/290) and 46% (145/318) of patients demonstrated a ≥ 2-grade improvement from baseline in forehead line severity at maximum eyebrow elevation as compared to 0% (0/101) and 1% (1/156) in placebo, as assessed by both investigators and subjects.[10]

moderate to severe

LATERAL CANTHAL LINES (24 Units)

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum smile before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30, 26.1% (58/222) and 20.3% (62/306) of patients demonstrated a ≥ 2-grade improvement from baseline in lateral canthal line severity at maximum smile as compared to 1.3% (3/223) and 0% (0/306) in placebo, as assessed by both investigators and subjects.[10]

moderate to severe

GLABELLAR LINES (20 Units)

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum frown before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30 as assessed by investigators, 80% (325/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 3% (4/132) in placebo. In clinical trials at Day 30 as evaluated by patients, 89% (362/405) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 7% (9/132) in placebo.[10]

JUVÉDERM®

COLLECTION OF FILLERS

Real patient. ***Results may vary.***
Treated with JUVÉDERM® 3 months after treatment with BOTOX® Cosmetic.

Unretouched photos of paid model taken before and 1 month after treatment. A total of 6.0 mL of JUVÉDERM® VOLUMA® XC was injected into the cheek area.

In the JUVÉDERM® VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.[14]

Landerson, 34

Landerson was treated with BOTOX® Cosmetic in the forehead lines, lateral canthal lines, and glabellar lines, along with JUVÉDERM® VOLUMA® XC in the cheeks.
Results may vary.

The safety and efficacy of these products for combined use have not been studied.

JUVÉDERM® Collection of Fillers IMPORTANT SAFETY INFORMATION (continued)

WARNINGS

- Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
- Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled

Please see additional Important Safety Information for the JUVÉDERM® Collection of Fillers on following pages.

BOTOX® COSMETIC onabotulinumtoxinA injection

moderate to severe

FOREHEAD LINES (20 Units)

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum eyebrow elevation before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30, 61% (178/290) and 46% (145/318) of patients demonstrated a ≥ 2-grade improvement from baseline in forehead line severity at maximum eyebrow elevation as compared to 0% (0/101) and 1% (1/156) in placebo, as assessed by both investigators and subjects.[10]

moderate to severe

LATERAL CANTHAL LINES (24 Units)

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum smile before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30, 26.1% (58/222) and 20.3% (62/306) of patients demonstrated a ≥ 2-grade improvement from baseline in lateral canthal line severity at maximum smile as compared to 1.3% (3/223) and 0% (0/306) in placebo, as assessed by both investigators and subjects.[10]

moderate to severe

GLABELLAR LINES (20 Units)

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum frown before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30 as assessed by investigators, 80% (325/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 3% (4/132) in placebo. In clinical trials at Day 30 as evaluated by patients, 89% (362/405) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 7% (9/132) in placebo.[10]

JUVÉDERM®

COLLECTION OF FILLERS

Real patient. ***Results may vary.***
Treated with JUVÉDERM® 3 months after treatment with BOTOX® Cosmetic.

Unretouched photos of paid model taken before and 1 month after treatment. A total of 7.0 mL of JUVÉDERM® VOLUMA® XC was injected into the cheek area, and a total of 2.4 mL of JUVÉDERM® VOLUMA® XC was injected into the chin area.

In the JUVÉDERM® VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction. In the clinical trial for chin, the total volume injected ranged from 0.7 mL to 4.0 mL, with a median of 2.4 mL, to achieve optimal correction.[14]



Real patient. ***Results may vary.***
Unretouched photos taken before and 1 month after treatment. A total of 2.4 mL of JUVÉDERM® VOLUMA® XC was injected into the chin area.

Whitney, 37

Whitney was treated with BOTOX® Cosmetic in the forehead lines, lateral canthal lines, and glabellar lines, along with JUVÉDERM® VOLUMA® XC in the cheeks and chin. **Results may vary.**

The safety and efficacy of these products for combined use have not been studied.

JUVÉDERM® Collection of Fillers IMPORTANT SAFETY INFORMATION (continued)

PRECAUTIONS

- To minimize the risks of potential complications, this product should only be used by healthcare professionals with appropriate experience and training on facial anatomy and product use in indicated area(s), vasculature, safe injection techniques, and identification and management of potential adverse events, including intravascular complications
- The potential risks of soft-tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications
- The safety and effectiveness for the treatment of anatomic regions other than indicated areas for each product have not been established in controlled clinical studies
- The safety for use of these products during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
- The safety for use of JUVÉDERM® VOLUMA® XC has been established in patients between 35 and 65 years of age for cheek augmentation and in patients between 22 and 80 years of age for chin augmentation
- The safety for use of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC in patients under 18 years, and JUVÉDERM® VOLLURE® XC and JUVÉDERM® VOLBELLA® XC in patients under 22 years, has not been established
- As with all transcutaneous procedures, dermal filler implantation carries a risk of infection
- Dermal fillers should be used with caution in patients on immunosuppressive therapy
- Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
- Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events

Please see additional Important Safety Information for the JUVÉDERM® Collection of Fillers on following pages.

BOTOX® COSMETIC onabotulinumtoxinA injection

moderate to severe

FOREHEAD LINES (20 Units)

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum frown before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30 as assessed by investigators, 80% (325/405) of patients demonstrated none or mild glabellar line severity at maximum frown as compared to 3% (4/132) in placebo. In clinical trials at Day 30 as evaluated by patients, 89% (362/405) of patients achieved at least a moderate improvement in their glabellar line appearance compared to 7% (9/132) in placebo.[10]

moderate to severe

LATERAL CANTHAL LINES (24 Units)

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum smile before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30, 26.1% (58/222) and 20.3% (62/306) of patients demonstrated a ≥ 2-grade improvement from baseline in lateral canthal line severity at maximum smile as compared to 1.3% (3/223) and 0% (0/306) in placebo, as assessed by both investigators and subjects.[10]

moderate to severe

GLABELLAR LINES (20 Units)

Real patient treated for the appearance of moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Results may vary.
Unretouched photos taken at maximum eyebrow elevation before and after treatment with BOTOX® Cosmetic at Day 30. In clinical trials at Day 30, 61% (178/290) and 46% (145/318) of patients demonstrated a ≥ 2-grade improvement from baseline in forehead line severity at maximum eyebrow elevation as compared to 0% (0/101) and 1% (1/156) in placebo, as assessed by both investigators and subjects.[10]

JUVÉDERM®

COLLECTION OF FILLERS

Real patient. ***Results may vary.***
Treated with JUVÉDERM® 3 months after treatment with BOTOX® Cosmetic.

Unretouched photos of paid model taken before and 1 month after treatment. A total of 3.0 mL of JUVÉDERM® VOLUMA® XC was injected into the cheek area. A total of 1.6 mL of JUVÉDERM® VOLLURE® XC was injected into the nasolabial folds and marionette lines. A total of 0.35 mL of JUVÉDERM® VOLBELLA® XC was injected into the lips (vermillion border) for lip augmentation.

In the JUVÉDERM® VOLUMA® XC clinical trial, the total volume injected ranged from 1.2 mL to 13.9 mL, with a median of 6.6 mL, to achieve optimal correction for all 3 subregions.[14]

Real patient. ***Results may vary.***
Unretouched photos taken before and 1 month after treatment. A total of 0.35 mL of JUVÉDERM® VOLBELLA® XC was injected into the lips (vermillion border) for lip augmentation.

Stephanie, 41

Stephanie was treated with BOTOX® Cosmetic in the forehead lines, lateral canthal lines, and glabellar lines, along with JUVÉDERM® VOLUMA® XC in the cheeks, JUVÉDERM® VOLLURE® XC in the nasolabial folds, and JUVÉDERM® VOLBELLA® XC in the lips.
Results may vary.

The safety and efficacy of these products for combined use have not been studied.

JUVÉDERM® Collection of Fillers IMPORTANT SAFETY INFORMATION (continued)

PRECAUTIONS (continued)

- If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site
- The safety for use of JUVEDERM® VOLUMA® XC injectable gel in patients with very thin skin in the mid-face has not been established
- The safety of JUVÉDERM® VOLUMA® XC with cannula for cheek augmentation has not been established in patients with Fitzpatrick Skin Types V and VI
- JUVÉDERM® VOLUMA® XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin augmentation study
- The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
- Patients may experience late-onset adverse events with use of these dermal fillers, and late-onset nodules with use of JUVÉDERM® VOLUMA® XC
- Based on preclinical studies, patients should be limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (130 lbs) body mass per year. The safety of injecting greater amounts has not been established

ADVERSE EVENTS
The most commonly reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA® XC, dryness was also reported. The majority were mild or moderate in severity. For JUVÉDERM® VOLUMA® XC, most resolved within 2 to 4 weeks. For JUVÉDERM® VOLLURE® XC, JUVÉDERM® Ultra Plus XC, or JUVÉDERM® Ultra XC, most resolved within 14 days; and for JUVÉDERM® VOLBELLA® XC, most resolved within 30 days.

To report an adverse reaction with any product in the JUVÉDERM® Collection, please call the Allergan® Product Support Department at 1-877-345-5372. Please visit JuvedermDFU.com for more information.

Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

A DUO TO TALK ABOUT

BOTOX® Cosmetic (onabotulinumtoxinA) and JUVÉDERM® Collection of Fillers are **the most requested brands**[3,5,*] to help your patients meet their aesthetic goals.

BOTOX® COSMETIC onabotulinumtoxinA injection

The #1 selling neurotoxin[20,†]

JUVÉDERM® COLLECTION OF FILLERS

The #1 chosen dermal filler brand[19,‡]

A DUO Powered by Allergan Aesthetics

Allergan Medical Institute

World-class continuum of hands-on or virtual education programs responsible for **training more than 32,000 professionals in 6 months.**[21,§]

ALLERGAN PARTNER PRIVILEGES | APP™

Your virtual partner, offering a range of **rebates and discounts for your practice**—the more products you buy, the greater the rebates.

Allē

Exclusive patient loyalty program to earn and redeem savings on aesthetic products and treatments.

The safety and efficacy of these products for combined use have not been studied.

*Based on an online survey of 526 neurotoxin users. Patients were asked if they ever requested to receive a specific brand of neurotoxin, and if so, which brand. And in a national online survey of 242 healthcare professionals, HCPs reported JUVÉDERM® products are requested more than any other filler brands.
†As of September 2021.
‡Based on market share of filler brands in 2021.
§Based on healthcare professionals trained across all Allergan Medical Institute live and on-demand programs/trainings across all Allergan Aesthetic brands.

References: 1. Data on file, Allergan, March, 2021: Consumer Filler. **2.** Data on file, Allergan, 2021; HCP Facial Injectables ATU: Neurotoxins—Final Report. **3.** Data on file, Allergan, February 2021; Consumer NTX. **4.** Data on file, Allergan, 2021; Injection areas data. **5.** Data on file, Allergan, February 1, 2021; HCP Facial Fillers ATU: Final Report. **6.** Data on file, Allergan, 2020; JUVÉDERM® and BOTOX® Cosmetic Treatment Frequency Comparison. **7.** Data on file, Allergan, 2021; JUVÉDERM® consumer usage summary. **8.** Humphrey S, Trindade de Almeida A, Safa M, et al. Enhanced patient retention after combination vs single modality treatment using hyaluronic acid filler and neuromodulator: A multicenter, retrospective review by The Flame Group. *J Cosmet Dermatol.* 2021;20:1495-1498. **9.** Data on file, Allergan, 2016-2019; Patient Transaction Record. **10.** BOTOX Cosmetic® Prescribing Information, February 2021. **11.** *Dysport*® Prescribing Information, July 2020. **12.** *Xeomin*® Prescribing Information, April 2021. **13.** *Jeuveau*® Prescribing Information, January 2020. **14.** JUVÉDERM® VOLUMA® XC Directions for Use, November 2020. **15.** JUVÉDERM® Ultra Plus XC Directions for Use, July 2020. **16.** JUVÉDERM® VOLLURE™ XC Directions for Use, July 2020. **17.** JUVÉDERM® Ultra XC Directions for Use, July 2020. **18.** JUVÉDERM® VOLBELLA™ XC Directions for Use, July 2020. **19.** Data on file, Allergan, September 2021; Dermal Filler Aesthetic Monthly Tracker. **20.** Data on file, Allergan, October 2021; Neurotoxin Monthly Tracker. **21.** Data on file, Allergan, 2021; Number of HCPs trained.

Allergan Aesthetics
an AbbVie company

hcp.BotoxCosmetic.com 1-800-BOTOXMD **hcp.Juvederm.com** MBD151753 01/22 012595